B. Riley Financial Reaffirms “Buy” Rating for Microbot Medical (NASDAQ:MBOT)

Microbot Medical (NASDAQ:MBOT)‘s stock had its “buy” rating reaffirmed by equities researchers at B. Riley Financial in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $4.00 target price on the biotechnology company’s stock, down from their previous target price of $5.00. B. Riley Financial’s target price would suggest a potential upside of 146.31% from the company’s current price.

A number of other analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research report on Tuesday, July 14th. Loop Capital set a $4.00 price target on shares of Microbot Medical in a research note on Wednesday, June 3rd. Zacks Research raised shares of Microbot Medical from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.38.

Microbot Medical Stock Performance

Shares of MBOT traded down $0.06 during trading hours on Friday, reaching $1.62. 668,963 shares of the company traded hands, compared to its average volume of 1,516,209. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The stock’s fifty day moving average is $1.82 and its 200 day moving average is $2.06. Microbot Medical has a 1-year low of $1.60 and a 1-year high of $4.67. The stock has a market cap of $109.08 million, a P/E ratio of -6.75 and a beta of 1.06.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.20 million. Equities research analysts anticipate that Microbot Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical in the 1st quarter worth about $57,000. Geode Capital Management LLC lifted its holdings in Microbot Medical by 24.7% during the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock valued at $996,000 after purchasing an additional 78,121 shares during the last quarter. American Century Companies Inc. bought a new position in Microbot Medical during the 2nd quarter valued at about $32,000. XTX Topco Ltd acquired a new position in Microbot Medical in the second quarter valued at about $43,000. Finally, Envestnet Asset Management Inc. bought a new stake in Microbot Medical during the third quarter worth about $98,000. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.